OTLK Stock Analysis: Buy, Sell, or Hold?
OTLK - Outlook Therapeutics, Inc. Common Stock
$1.73
0.18 (11.61%)
▲
5d:
+18.49%
30d:
+57.27%
90d:
+580.03%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
28d
Get Alerted When OTLK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
20 traders called OTLK this week
92% bullish • 2 bearish
92% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: OTLK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: OTLK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: OTLK is currently trading at $1.73, which is considered slightly high relative to its 30-day fair value range of $1.10 to $1.76.
Technical Outlook: Technically, OTLK is in a uptrend. The price is approaching resistance at $0.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 11.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+217.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OTLK is in a uptrend. The price is approaching resistance at $0.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 11.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+217.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.10 -
$1.76
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+11.6%)
- BULLISH: Trading 217.9% below Wall St target ($5.50)
Trading Range Analysis
30-Day Trading Range
$1.10 -
$1.76
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.40
Resistance Level
$0.94
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.86
Wall Street Target
$5.50
(+217.9%)
Revenue Growth (YoY)
658.3%
Share & Embed Analysis
Last updated: July 14, 2026 7:49 PM ET
Data refreshes hourly during market hours. Next update: 8:49 PM
Data refreshes hourly during market hours. Next update: 8:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OTLK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 64 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 55 HOLD |
